Using group testing in a two-phase epidemiologic design to identify the effects of a large number of antibody reactions on disease risk

BMC Medical Research Methodology

Research

Yaakov Malinovsky¹  Tanvi Mehta²  Christian C. Abnet²  Paul S. Albert² 

[1] Department of Mathematics and Statistics, University of Maryland, Baltimore County, Baltimore, MD, USA;Division of Cancer Epidemiology and Genetics, National Cancer Institute, 9609 Medical Center Drive, Room SG/7E146, 20850, Rockville, MD, USA;

关键词: Case-control studies;    Epidemiologic design;    Group Testing;    Prevalence estimation;   

DOI  :  10.1186/s12874-022-01798-0

 received in 2022-01-18, accepted in 2022-11-21,  发布年份 2022

来源: Springer

【 摘 要 】

BackgroundThe role of immunological responses to exposed bacteria on disease incidence is increasingly under investigation. With many bacterial species, and many potential antibody reactions to a particular species, the large number of assays required for this type of discovery can make it prohibitively expensive. We propose a two-phase group testing design to more efficiently screen numerous antibody effects in a case-control setting.MethodsPhase 1 uses group testing to select antibodies that are differentially expressed between cases and controls. The selected antibodies go on to Phase 2 individual testing.ResultsWe evaluate the two-phase group testing design through simulations and example data and find that it substantially reduces the number of assays required relative to standard case-control and group testing designs, while maintaining similar statistical properties.ConclusionThe proposed two-phase group testing design can dramatically reduce the number of assays required, while providing comparable results to a case-control design.

【 授权许可】

CC BY   
© This is a U.S. Government work and not under copyright protection in the US; foreign copyright protection may apply 2022

【 图 表 】

12888_2022_4365_Article_IEq5.gif

12982_2022_119_Article_IEq99.gif

12982_2022_119_Article_IEq98.gif

12888_2022_4365_Article_IEq4.gif

12888_2022_4365_Article_IEq3.gif

12888_2022_4365_Article_IEq2.gif

12982_2022_119_Article_IEq94.gif

12888_2022_4365_Article_IEq1.gif

12982_2022_119_Article_IEq92.gif

12982_2022_119_Article_IEq230.gif

12982_2022_119_Article_IEq223.gif

12982_2022_119_Article_IEq218.gif